Cargando…

Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management

Detalles Bibliográficos
Autores principales:	Heskin, Joseph, Pallett, Scott J C, Mughal, Nabeela, Davies, Gary W, Moore, Luke S P, Rayment, Michael, Jones, Rachael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718360/ https://www.ncbi.nlm.nih.gov/pubmed/34973713 http://dx.doi.org/10.1016/S0140-6736(21)02657-X

Ejemplares similares

Healthcare worker perceptions of routine asymptomatic SARS-CoV-2 screening using lateral flow assays: A qualitative analysis across two London hospitals.
por: Heskin, Joseph, et al.
Publicado: (2021)

Early identification of high-risk individuals for monoclonal antibody therapy and prophylaxis is feasible by SARS-CoV-2 anti-spike antibody specific lateral flow assay
por: Pallett, Scott J.C., et al.
Publicado: (2022)

Serological assays for delayed SARS-CoV-2 case identification – Author's reply
por: Pallett, Scott J C, et al.
Publicado: (2020)

Optimising the initial investigation of suspected cases of SARS-CoV-2 reinfection
por: Pallett, Scott JC., et al.
Publicado: (2021)

Characterising differential antibody response is integral to future SARS-CoV-2 serostudies
por: Pallett, Scott John Charles, et al.
Publicado: (2020)

Real-world evaluation of COVID-19 lateral flow device (LFD) mass-testing in healthcare workers at a London hospital; a prospective cohort analysis
por: Lamb, Georgia, et al.
Publicado: (2021)

Total synthesis of antiviral drug, nirmatrelvir (PF-07321332)
por: Shekhar, Chandra, et al.
Publicado: (2022)

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants
por: Pallett, Scott J C, et al.
Publicado: (2022)

Structured serological testing is an essential component to investigating SARS-CoV-2 reinfection
por: Pallett, Scott J C, et al.
Publicado: (2021)

Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332
por: Li, Jian, et al.
Publicado: (2022)

The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations
por: Joyce, Ryan P., et al.
Publicado: (2022)

Structural basis of main proteases of HCoV-229E bound to inhibitor PF-07304814 and PF-07321332
por: Zhou, Yanru, et al.
Publicado: (2023)

EE495 Threshold Price in the US to Achieve Cost-Effective Use of Molnupiravir and PF-07321332/Ritonavir for the Prevention of Severe COVID-19 in High-Risk Adults
por: Majda, T, et al.
Publicado: (2022)

Risk of omicron infection for high-risk older adults in long-term care facilities
por: Pallett, Scott J C, et al.
Publicado: (2023)

Evaluating the performance characteristics of five lateral flow assays for the detection of the SARS-CoV-2 nucleocapsid antigen
por: Heskin, J., et al.
Publicado: (2022)

Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332
por: Zhao, Yao, et al.
Publicado: (2021)

Insights into the binding and covalent inhibition mechanism of PF-07321332 to SARS-CoV-2 M(pro)
por: Ngo, Son Tung, et al.
Publicado: (2022)

Association between SARS-CoV-2 exposure and antibody status among healthcare workers in two London hospitals: a cross-sectional study
por: Murongazvombo, Admire S., et al.
Publicado: (2021)

Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease
por: Macchiagodena, Marina, et al.
Publicado: (2022)

PF‐07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID‐19 patients
por: Hau, Raymond K., et al.
Publicado: (2022)

Non-invasive saliva specimens for the diagnosis of COVID-19: caution in mild outpatient cohorts with low prevalence
por: Skolimowska, Keira, et al.
Publicado: (2020)

Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 M(pro) inhibitor in animal models
por: Catlin, N.R., et al.
Publicado: (2022)

The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern
por: Abdelnabi, Rana, et al.
Publicado: (2022)

Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: a prospective multicentre cohort study
por: Pallett, Scott J C, et al.
Publicado: (2020)

Variability in detection of SARS-CoV-2-specific antibody responses following mild infection: a prospective multicentre cross-sectional study, London, United Kingdom, 17 April to 17 July 2020
por: Pallett, Scott JC, et al.
Publicado: (2022)

Hybrid immunity in older adults is associated with reduced SARS-CoV-2 infections following BNT162b2 COVID-19 immunisation
por: Pallett, Scott J. C., et al.
Publicado: (2023)

Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332
por: Pavan, Matteo, et al.
Publicado: (2021)

Rapid reconfiguration of sexual health services in response to UK autochthonous transmission of mpox (monkeypox)
por: Heskin, Joseph, et al.
Publicado: (2023)

Ritonavir-boosted Nirmatrelvir and COVID-19 outcomes in the age of Omicron variant
por: Imran, Laiba, et al.
Publicado: (2023)

Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations
por: Ahmad, Bilal, et al.
Publicado: (2021)

Caution Required in the Use of Administrative Data and General Laboratory Submissions for Influenza Vaccine Effectiveness Estimation
por: Skowronski, Danuta M, et al.
Publicado: (2019)

UNMODIFIED ECT: A NOTE OF CAUTION
por: Andrade, Chittaranjan
Publicado: (1995)

Silver-Coated Pills—A Caution
por: Cleghorn, James
Publicado: (1877)

Hindustani Examinations: Caution to Junior Assistant-Surgeons
Publicado: (1866)

Drug-induced Liver Injury With Ritonavir-Boosted Nirmatrelvir: Evidence From Coronavirus Disease 2019 Emergency Use Authorization Adverse Event Reporting System
por: Li, Guo-Fu, et al.
Publicado: (2023)

Ritonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients
por: Nishijima, Takeshi, et al.
Publicado: (2013)

Caution is needed when assessing results of home birth
por: Verd, Sergio, et al.
Publicado: (2019)

COVID-19, ECMO, and lymphopenia: a word of caution
por: Henry, Brandon Michael
Publicado: (2020)

Caution against corticosteroid-based COVID-19 treatment
por: Tang, Chong, et al.
Publicado: (2020)

Caution When Comparing the Impact of Corticosteroids in COVID-19
por: Confalonieri, Marco, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gj1oh4qbrlnbp34npucbucl6br